Comparing central vein stenosis from dialysis catheters in subclavian versus jugular veins
Central Venous Stenosis Incidence After Right-sided Subclavian and Internal Jugular Vein Catheterization With a Silicone Temporary Hemodialysis Catheter
This study is testing whether using temporary dialysis catheters in the subclavian or jugular veins leads to fewer problems with vein narrowing for patients needing hemodialysis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Skane University Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Lund) |
| Trial ID | NCT04871568 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the incidence of central vein stenosis (CVS) resulting from temporary hemodialysis catheterization in either the subclavian or jugular veins. It is a multicentric, prospective, randomized, controlled, assessor-blinded trial conducted in three hospitals in southern Sweden. Patients will be randomly assigned to receive a silicone temporary central dialysis catheter (tCDC) in either vein, with follow-up assessments including CT venography and ultrasound to evaluate CVS. The study aims to provide insights into the safety and efficacy of catheter placement techniques.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who require a temporary central dialysis catheter for at least 7 days.
Not a fit: Patients with existing central venous interventions, known right-sided central vein stenosis, or other specific exclusions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved catheterization practices that minimize the risk of central vein stenosis for dialysis patients.
How similar studies have performed: Previous studies have indicated varying results regarding the incidence of CVS with different catheter placements, making this approach both relevant and necessary for further investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (18 years of age or older). * In need of a tCDC with an expected treatment time of at least 7 days. * Informed consent. Exclusion Criteria: * Intravenous pacemaker or a PICC-line via right-sided central veins in situ. * Known right-sided CVS. * AV fistula on the right upper extremity. * History of central venous vascular interventions including stents, dilatations and more (but not previous central venous catheterization). * Central venous catheter in the right internal jugular vein or in the right subclavian vein in situ. * Either the right jugular vein or the right subclavian vein unavailable for catheterization due to, e.g., local skin infection, thrombosis or inability to visualize the vein with ultrasound. * Known allergy to iodinated contrast agents. * BMI \>35 kg/m2. * No study physician available for the catheterization.
Where this trial is running
Lund
- Skånes universitetssjukhus — Lund, Sweden (Recruiting)
Study contacts
- Principal investigator: Ola Borgquist, MD, PhD — Skånes universitetssjukhus
- Study coordinator: Ola Borgquist, MD, PhD
- Email: oborgquist@gmail.com
- Phone: +46704156334
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.